Sign in or create an account to add this stock to your watchlist.
About Anadys Pharmaceuticals (NASDAQ:ANDS)
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing medicines for the treatment of hepatitis C. The Company is focusing on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway for the treatment of hepatitis C. In January 2011, the Company initiated a Phase IIb clinical study of ANA598 in combination with SOC for the treatment of hepatitis C. In the Phase IIb study, approximately 200 chronically infected genotype 1 hepatitis C patients are to receive ANA598 200 mg bid in combination with standard of care (SOC), with a loading dose of 800 mg ANA598 bid on day one. In addition, approximately 66 chronically infected genotype 1 hepatitis C patients are to receive placebo added to SOC.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Anadys Pharmaceuticals (NASDAQ:ANDS) Frequently Asked Questions
What is Anadys Pharmaceuticals' stock symbol?
Anadys Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANDS."
Has Anadys Pharmaceuticals been receiving favorable news coverage?
Media stories about ANDS stock have been trending somewhat positive on Sunday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anadys Pharmaceuticals earned a daily sentiment score of 0.24 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Anadys Pharmaceuticals?
Shares of ANDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Anadys Pharmaceuticals?
Anadys Pharmaceuticals' mailing address is Suite 200, 5871 Oberlin Drive, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-5303600.
MarketBeat Community Rating for Anadys Pharmaceuticals (ANDS)MarketBeat's community ratings are surveys of what our community members think about Anadys Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Anadys Pharmaceuticals (NASDAQ:ANDS) Analyst Ratings History
(Data available from 5/27/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Anadys Pharmaceuticals (NASDAQ:ANDS) Earnings History and Estimates Chart
Anadys Pharmaceuticals (NASDAQ ANDS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Anadys Pharmaceuticals (NASDAQ:ANDS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Anadys Pharmaceuticals (NASDAQ ANDS) Insider Trading and Institutional Ownership History
Anadys Pharmaceuticals (NASDAQ ANDS) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Anadys Pharmaceuticals (NASDAQ ANDS) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Anadys Pharmaceuticals (NASDAQ:ANDS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Anadys Pharmaceuticals (NASDAQ:ANDS) Income Statement, Balance Sheet and Cash Flow Statement
Anadys Pharmaceuticals (NASDAQ ANDS) Stock Chart for Sunday, May, 27, 2018